Sign in
4

Changes in Ownership

Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000077

General Counsel sold 52,000 shares at an average $108.49 ($5,641,409)

  • General Counsel acquired 52,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Quinlan Paul T · General Counsel

Table I: Non-derivative

8 lines
Date Transaction Shares Price Value Owned after D/I
2026-08-14 Exercise or conversion : show line 1 in the form 10b5-1 +10,000 $7.80 $78,000 41,034 D
2026-08-14 Exercise or conversion : show line 2 in the form 10b5-1 +42,000 $12.50 $525,000 83,034 D
2026-08-14 Sale : show line 3 in the form 10b5-1 −3,630 $106.05 $384,963 79,404 D
2026-08-14 Sale : show line 4 in the form 10b5-1 −10,434 $107.14 $1,117,901 68,970 D
2026-08-14 Sale : show line 5 in the form 10b5-1 −14,696 $107.97 $1,586,779 54,274 D
2026-08-14 Sale : show line 6 in the form 10b5-1 −10,200 $109.11 $1,112,954 44,074 D
2026-08-14 Sale : show line 7 in the form 10b5-1 −9,193 $110.00 $1,011,266 34,881 D
2026-08-14 Sale : show line 8 in the form 10b5-1 −3,847 $111.14 $427,547 31,034 D
Open-market sales · 52,000 sh · avg $108.49 · $5,641,409

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2026-08-14 Exercise or conversion : show line 9 in the form 10b5-1 Employee Warrant (right to buy) −10,000 89,996 D
2026-08-14 Exercise or conversion : show line 10 in the form 10b5-1 Employee Stock Option (right to buy) −42,000 120,500 D
Loading xslF345X06/form4.xml…